Western Queensland PHN - COVID-19 Weekly Update

09 May 2022

Dear Practice and Pharmacy Staff,
Please see this week’s collection of updates and links for COVID Care and Vaccinations.


ATAGI updates on post-infection COVID-19 vaccinations and extended mRNA intervals

Australian Technical Advisory Group on Immunisation (ATAGI), have updated the following recommendations.

  • Dose interval between primary doses should be extended to 8 weeks for both Pfizer and Moderna vaccines.

  • People should wait 3 months after confirmed SARS-CoV-2 (the virus that causes COVID-19) infection before they receive their next COVID-19 vaccine dose

More information

Vaccination Locations in Western Queensland

The list of Vaccination Clinics in Western Queensland is updated weekly. It includes General Practices, Pharmacies and HHS outreach clinics and is available on the WQPHN website.
Please email Melissa Williams to notify WQPHN of any change you want to your listing.


Reminder: Diagnosed cases

Diagnosed cases of COVID-19 still need to isolate for 7 days which can end if they no longer have a fever, sore throat, runny nose or cough that is bad or getting worse. If they still have symptoms, they need to stay in isolation until they’re asymptomatic.

Reminder: Guidelines about close contacts in Queensland

Asymptomatic close contacts no longer need to isolate at home, however for 7 days from the last time someone in their household tested positive for COVID-19 they need to:

  • monitor for symptoms

  • wear a mask at all times when outside the home

  • not visit vulnerable settings, such as hospitals, aged care and disability facilities, unless in exceptional or compassionate circumstances (for example, end of life visits)

  • test for COVID-19 if they develop symptoms.

It is also reommended that they:

  • avoid large gatherings or crowded indoor events

  • work or study from home if you can.

Isolation for Diagnosed Cases of COVID-19 and Management of Close Contacts Direction (No. 7)
Guidelines for close contacts in Queensland.


Pre-exposure prevention of COVID-19

On 24 February 2022 the Therapeutic Goods Administration (TGA) granted provisional approval to AstraZeneca Pty Ltd for its tixagevimab and cilgavimab (EVUSHELD) for the prevention of COVID-19 in people who are at risk of infection but have not been exposed to the virus, known as pre-exposure prevention of COVID-19.

EVUSHELD has been granted provisional approval for the pre-exposure prophylaxis (prevention) of COVID-19 in people aged 12 years and older weighing at least 40 kg:

who have moderate-to-severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments that make it likely that they will not mount an adequate immune response to COVID-19 vaccination; or

for whom vaccination is not recommended due to a history of severe adverse reaction to a COVID‐19 vaccine or COVID‐19 vaccine component.

Pre-exposure prevention with EVUSHELD is not a substitute for vaccination in individuals for whom COVID-19 vaccination is recommended.

The National Medical Stockpile (NMS) distributes these treatments to state and territory governments for use in their health systems. For more information, visit the Therapeutic Goods Administration website.


New evidence briefs

The NSW Health COVID-19 Critical Intelligence Unit has provided new evidence briefs on:
Chest pain and dyspnoea following COVID-19 vaccination, and
Ongoing breathlessness post COVID-19

This resource provides information on two questions.

1. How to determine those patients who present with ongoing breathlessness in need of urgent review or intervention due to suspected pulmonary embolus? 

2. What is the evidence-based management approach for breathlessness as a symptom of post-acute sequelae of COVID-19?

Optimising the supply of PPE

The new ‘Optimising the supply of personal protective equipment (PPE) guideline’, provides recommendations on the optimal use of PPE as a way of managing disrupted supply chain. 

Developed by the PPE Working Group, with consultation from the Statewide Infection Clinical Network and the Work Health and Safety Advisory Group, the working group took an evidence-based approach to rewriting the existing PPE conservation guidance
Link to guideline




For the latest state and national COVID-19 guidance view details at WQ HealthPathways.
General practitioners should refer to HealthPathways for up-to-date information on the clinical management of people with moderate risk, including escalation pathways if people deteriorate and for referral to oral treatments.


Qld PHNs webinar series: COVID update for general practice #6

Winter Readiness: The Coincidence of Influenza and COVID-19

Date:  Thursday, 12 May

Time:  6:30pm - 8:00pm

Join us as we discuss the impact of the flu season and continuing presence of COVID-19.


Dr Steven Donohue (Director, Townsville PHU)
Epidemiology of Influenza, outbreaks and what is ahead this winter.

Dr Trent Yarwood (Infectious Disease Specialist)
Double dose: COVID-19 and Influenza, Current influenza treatments, Vulnerable patients

Dr Karen Benn (GP) South West Queensland
A General Practice perspective to Winter Readiness.  Overview of Influenza/Respiratory conditions and COVID-19 in HealthPathways.

To submit a question in advance, email to  

Register Here


WQPHN COVID-19 Response Contacts

Kathleen O’Hara, Program Manager, COVID-19 Response 
Email: Phone: 0456 001 789

Sarah Carige, Coordinator, COVID-19 Response
Email: Phone: 0417 745 342

Melissa Williams, Coordinator, COVID-19 Response
Email: Phone: 0448 999 218

Western Queensland Primary Health Network gratefully acknowledges the financial and other support from the Australian Government Department of Health


Although funding has been provided by the Australian Government, the material contained herein does not necessarily represent the views
or policies of, nor is endorsed by, the Australian Government.

This email was sent to <<Email Address>>
why did I get this?    unsubscribe from this list    update subscription preferences
Western Queensland PHN · 11 Barkly Highway RFDS Base · Mount Isa, QLD 4825 · Australia